查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678512

全球 GLP-1促效劑減重藥市場：市場規模、市場佔有率、趨勢分析（按藥物、給藥途徑、分銷管道和地區）、按細分市場預測（2025-2030 年）

GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis By Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), By Route of Administration, By Distribution Channel, By Region, And Segment forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 153 Pages | 商品交期: 2-10個工作天內

價格

GLP-1促效劑減重藥物市場的成長與趨勢：

根據Grand View Research的最新報告，全球GLP-1促效劑減重藥物市場規模預計到2030年將達到488.4億美元，2025年至2030年期間的複合年成長率為18.54%。

減重治療中對 GLP-1促效劑（例如 Semaglutide (Wegovy)、利拉魯肽 (Saxenda) 和 Tirzepatide (促效劑)）的需求正在為醫療保健領域帶來巨大的商機。這些藥物在控制肥胖和代謝狀況方面表現出了有效的效果，正在推動市場的成長。雖然Semaglutide(Wegovy) 和利拉魯Liraglutide(Saxenda) 已經成為可靠的減重療法，但替澤帕肽 (Zepbound) 與同類藥物相比表現出了更高的療效，並成為一種有前途的選擇。這些藥物透過調節食慾和提高胰島素敏感性發揮作用，隨著越來越多的臨床證據支持其使用，GLP-1促效劑在肥胖症治療中越來越受歡迎。

口服製劑的引入不僅使這些治療方法更容易獲得，而且還將擴大青睞非注射治療方法的患者群。藥局在 GLP-1促效劑的分銷中發揮越來越重要的作用。零售藥局因可配發 Wegovy 和 Saxenda處方箋廣受歡迎，它們不僅可以提供藥品，還可以為肥胖管理者提供病患教育和持續支援。憑藉便捷的藥物補充和諮詢服務，零售藥局在支持長期減重管理方面發揮著至關重要的作用。

雖然醫院藥局仍然發揮著重要作用，特別是當患者開始治療並需要密切監測時，但隨著患者轉向長期護理，零售藥局正在發揮更重要的作用。由於醫療管理的重要性，醫院藥局在治療的早期階段非常重要，但隨著病患病情穩定和治療進展，通常會轉向零售或專業藥局。這些藥房在提供持續治療和提供專業服務方面發揮著至關重要的作用。

專科藥局和網路藥局也開始參與 GLP-1促效劑減重藥的分銷。這些藥局可以為患者提供客製化服務，例如送貨上門和個人化用藥諮詢，這對那些接受長期治療方法的患者尤其有益。擴大藥局的作用可以為需要持續接受減重治療的患者提供更多的便利和支持。

肥胖症是一個重大的公共衛生問題，人們對防治肥胖症的興趣日益濃厚，這推動了 GLP-1促效劑減重藥物產業的擴張。隨著人們對肥胖相關的長期健康風險（如第二型糖尿病、心血管疾病和睡眠呼吸中止症）的認知越來越廣泛，對有效治療方法的需求也日益成長。 tirzepatide同時針對GLP-1和GIP受體，其新穎的作用機制因優異的療效而受到廣泛關注，這可能進一步推動對GLP-1促效劑的需求。

隨著對這些藥物的需求增加，挑戰也隨之而來，特別是在藥品分銷和供應鏈管理領域。注射療法的持續可用性需要強大的低溫運輸物流和高度重視病患教育，以最佳化藥物使用。此外，口服製劑的開發代表著提高可及性和依從性的重要機會，為製藥公司提供了服務更廣泛患者群體的新途徑。

GLP-1促效劑減重藥市場：分析概述

  • 依藥物分類，Semaglutide（wegovy）板塊將在2024年以60.70%的最大銷售佔有率領先市場，鞏固其作為肥胖管理首選治療選擇的地位。Semaglutide是此類治療領域的市場領導者，具有顯著減輕體重、改善代謝健康的功效，且臨床認可度不斷提高。
  • 根據給藥途徑，腸外藥物將在 2024 年以 92.7% 的銷售佔有率引領市場。這些注射療法每週或每兩週進行一次，因其在促進長期減肥和解決胰島素抗性等潛在代謝疾病方面被證明有效而受到青睞。
  • 按分銷管道分類，零售藥局部門在 2024 年佔據市場主導地位，銷售佔有率最大，為 55.46%。零售藥局提供的便利性和日益增強的可及性使其成為患者使用減重藥的主要網路基地台。
  • 由於醫療基礎設施發達、對神經系統疾病的高度認知以及先進治療方案的可用性等因素，預計北美將在 2024 年佔據最大的市場佔有率。該地區對研究和創新的高度重視進一步推動了市場成長。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. GLP-1促效劑減重藥市場：促進因素、趨勢與範圍

  • 母市場展望
  • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • GLP-1促效劑減重藥市場：分析工具
    • 波特的分析
    • PESTEL 分析

第 4 章 GLP-1促效劑減重藥物市場：藥物特定估計與趨勢分析

  • GLP-1促效劑減重藥市場：細分儀表板，依藥物分類
  • GLP-1促效劑減重藥市場：藥物趨勢分析（2024 年和 2030 年）
  • Semaglutide（Wegovy）
  • 利拉魯Liraglutide（Saxenda）
  • Tirzepatide（Zepbound）
  • 其他藥物

第 5 章 GLP-1促效劑減重藥市場：按給藥途徑進行的估計和趨勢分析

  • GLP-1促效劑減重藥市場：細分儀表板（依給藥途徑分類）
  • GLP-1促效劑減重藥市場：按給藥途徑分類的趨勢分析（2024 年和 2030 年）
  • 腸外
  • 口服

6. GLP-1促效劑減重藥市場：通路評估及趨勢分析

  • GLP-1促效劑減重藥市場：細分儀表板、通路
  • GLP-1促效劑減重藥市場：通路變化分析（2024 年和 2030 年）
  • 醫院藥房
  • 零售藥局
  • 其他藥局

第 7 章 GLP-1促效劑減重藥物市場：按地區分類的估計和趨勢分析

  • GLP-1促效劑減重藥市場佔有率（按地區分類） (2024 年和 2030 年)
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 南非

第8章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司分類
  • 公司市場佔有率分析（2024 年）
  • 企業熱圖分析（2024年）
  • 公司簡介
    • Eli Lilly and Company.
    • Pfizer Inc.
    • Novo Nordisk A/S
    • Viking Therapeutics
    • Structure Therapeutics
Product Code: GVR-4-68040-512-4

GLP-1 Agonists Weight Loss Drugs Market Growth & Trends:

The global GLP-1 agonists weight loss drugs market size is anticipated to reach USD 48.84 billion by 2030 and is projected to grow at a CAGR of 18.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The demand for GLP-1 Agonists in weight loss treatments, including Semaglutide (Wegovy), Liraglutide (Saxenda), and Tirzepatide (Zepbound), is fueling significant opportunities in the healthcare sector. These drugs, which have shown effective results in managing obesity and metabolic conditions, are driving market growth. Semaglutide (Wegovy) and Liraglutide (Saxenda) have already established themselves as reliable weight loss therapies, while Tirzepatide (Zepbound) is emerging as a promising option, showing even greater efficacy compared to other drugs in its class. These therapies work by regulating appetite and improving insulin sensitivity, and with growing clinical evidence supporting their use, the acceptance of GLP-1 Agonists in obesity management is increasing.

The introduction of oral versions would not only make these therapies more accessible but also broaden the patient base who prefer non-injection-based therapies. Pharmacies are playing an increasingly important role in the distribution of GLP-1 Agonists. Retail pharmacies, in particular, are gaining traction in fulfilling prescriptions for Wegovy and Saxenda, providing not only access to the medications but also patient education and ongoing support for those managing obesity. Retail pharmacies' ability to offer convenient medication refills and counseling services makes them crucial in supporting the long-term management of weight loss.

While hospital pharmacies are still key players, especially when patients start treatment and require close monitoring, retail pharmacies are taking on a more significant role as patients transition to long-term care. Hospital pharmacies are important during the initial stages of therapy, where medical supervision is critical, but as patients stabilize and progress with treatment, they often shift to retail or specialty pharmacies. These pharmacies play a vital role in providing continued access to therapy and offering specialized services.

Specialty pharmacies and online pharmacies are also becoming more involved in the distribution of GLP-1 Agonists weight loss drugs. These pharmacies can offer tailored services, such as home delivery and personalized medication counseling, which can be particularly beneficial for patients on long-term treatment regimens. By expanding their role, they provide added convenience and support for patients needing consistent access to weight loss therapies.

The growing focus on combating obesity, one of the leading public health challenges, is driving the expansion of the GLP-1 agonists weight loss drug industry. With increasing recognition of the long-term health risks associated with obesity, such as type 2 diabetes, cardiovascular disease, and sleep apnea, there is a rising demand for effective treatments. Tirzepatide's novel mechanism of action, which targets both GLP-1 and GIP receptors, is attracting considerable attention for its superior efficacy and could further boost demand for GLP-1 Agonists.

As the demand for these medications rises, challenges will emerge, particularly in the areas of drug distribution and supply chain management. Ensuring that injectable therapies are consistently available will require robust cold chain logistics and increased focus on patient education to optimize the use of the drugs. Moreover, the development of oral formulations represents a significant opportunity to improve accessibility and adherence, providing a new avenue for pharmaceutical companies to cater to a broader patient population.

GLP-1 Agonists Weight Loss Drugs Market Report Highlights:

  • Based on drug, the semaglutide (wegovy) segment led the market with the largest revenue share of 60.70% in 2024, solidifying its position as the preferred treatment option for obesity management. Semaglutide's proven efficacy in significantly reducing body weight and improving metabolic health, and its growing clinical acceptance make it the leading therapy in this class.
  • Based on route of administration, the parenteral segment led the market with the largest revenue share of 92.7% in 2024. These injectable therapies, administered either weekly or bi-weekly, are preferred due to their proven effectiveness in promoting long-term weight loss and addressing underlying metabolic conditions like insulin resistance.
  • Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 55.46% in 2024. The growing convenience and accessibility offered by retail pharmacies made them the primary point of access for patients using weight loss medications.
  • North America accounted for the largest market share in 2024, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. GLP-1 Agonists Weight Loss Drugs Market Variables, Trends, & Scope

  • 3.1. Parent Market Outlook
  • 3.2. Ancillary Market Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
      • 3.3.1.1. Rising prevalence of obesity
      • 3.3.1.2. Increasing adoption of weight loss drug therapy
      • 3.3.1.3. Rising geriatric population
    • 3.3.2. Market Restraints Analysis
      • 3.3.2.1. High cost of treatment
      • 3.3.2.2. Stringent regulations pertaining to production and approvals
  • 3.4. GLP-1 Agonists Weight Loss Drugs Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social Landscape
      • 3.4.2.3. Technological Landscape
      • 3.4.2.4. Environmental Landscape
      • 3.4.2.5. Legal Landscape

Chapter 4. GLP-1 Agonists Weight Loss Drugs Market: By Drug Estimates & Trend Analysis

  • 4.1. GLP-1 Agonists Weight Loss Drugs Market: Drug Segment Dashboard
  • 4.2. GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Semaglutide (Wegovy)
    • 4.3.1. Semaglutide (Wegovy) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Liraglutide (Saxenda)
    • 4.4.1. Liraglutide (Saxenda) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Tirzepatide (Zepbound)
    • 4.5.1. Tirzepatide (Zepbound) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Drugs
    • 4.6.1. Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Estimates & Trend Analysis

  • 5.1. GLP-1 Agonists Weight Loss Drugs Market: Route of Administration Segment Dashboard
  • 5.2. GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Parenteral
    • 5.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Segment Dashboard
  • 6.2. GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other Pharmacies
    • 6.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. GLP-1 Agonists Weight Loss Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. GLP-1 Agonists Weight Loss Drugs Market Share, By Region, 2024 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Norway
      • 7.3.8.1. Norway GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. Kuwait
      • 7.6.4.1. Kuwait GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa GLP-1 Agonists Weight Loss Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis, 2024
  • 8.5. Company Profiles
    • 8.5.1. Eli Lilly and Company.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Novo Nordisk A/S
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. Viking Therapeutics
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. Structure Therapeutics
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 4 Global GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 Global GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 North America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 8 North America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 11 U.S. GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 14 Canada GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Mexico GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 17 Mexico GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Europe GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 20 Europe GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 21 Europe GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 Europe GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 Germany GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 24 Germany GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 Germany GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 UK GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 27 UK GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 UK GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 France GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 30 France GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 France GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Italy GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 33 Italy GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Italy GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Spain GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 36 Spain GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 Spain GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 Denmark GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 39 Denmark GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Denmark GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 41 Sweden GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 42 Sweden GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 Sweden GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Norway GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 45 Norway GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Norway GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 51 China GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 52 China GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 53 China GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 54 Japan GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 55 Japan GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 56 Japan GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 India GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 58 India GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 59 India GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Korea GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 61 South Korea GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 62 South Korea GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Australia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 64 Australia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 65 Australia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Thailand GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 67 Thailand GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Thailand GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Latin America GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 70 Latin America GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 71 Latin America GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 Latin America GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Brazil GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 74 Brazil GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 Brazil GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 Argentina GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 77 Argentina GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 Argentina GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 83 South Africa GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 84 South Africa GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 85 South Africa GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 89 UAE GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 90 UAE GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 91 UAE GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 Kuwait GLP-1 Agonists Weight Loss Drugs, by Drugs, 2018 - 2030 (USD Million)
  • Table 93 Kuwait GLP-1 Agonists Weight Loss Drugs, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 94 Kuwait GLP-1 Agonists Weight Loss Drugs, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & forecasting
  • Fig. 6 Market formulation & Validation
  • Fig. 7 GLP-1 Agonists Weight Loss Drugs, Market Segmentation
  • Fig. 8 Market Snapshot, 2024
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five forces Analysis
  • Fig. 14 Global GLP-1 Agonists Weight Loss Drugs Market: By Drug Movement Analysis
  • Fig. 15 Global GLP-1 Agonists Weight Loss Drugs Market, for Semaglutide (Wegovy), 2018 - 2030 (USD Million)
  • Fig. 16 Global GLP-1 Agonists Weight Loss Drugs Market, for Liraglutide (Saxenda), 2018 - 2030 (USD Million)
  • Fig. 17 Global GLP-1 Agonists Weight Loss Drugs Market, for Tirzepatide (Zepbound), 2018 - 2030 (USD Million)
  • Fig. 18 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Drugs, 2018 - 2030 (USD Million)
  • Fig. 19 Global GLP-1 Agonists Weight Loss Drugs Market: By Route of Administration Movement Analys
  • Fig. 20 Global GLP-1 Agonists Weight Loss Drugs Market, for Parenteral 2018 - 2030 (USD Million)
  • Fig. 21 Global GLP-1 Agonists Weight Loss Drugs Market, for Oral, 2018 - 2030 (USD Million)
  • Fig. 22 Global GLP-1 Agonists Weight Loss Drugs Market: Distribution Channel Movement Analysis
  • Fig. 23 Global GLP-1 Agonists Weight Loss Drugs Market, for Hospital Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 24 Global GLP-1 Agonists Weight Loss Drugs Market, for Retail Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 25 Global GLP-1 Agonists Weight Loss Drugs Market, for Other Pharmacies, 2018 - 2030 (USD Million)
  • Fig. 26 Regional Marketplace: Key Takeaways GLP-1 Agonists Weight Loss Drugs Market, Region 2018 -
  • Fig. 27 Regional Outlook, 2022 & 2030 GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 28 Global GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 29 North America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 30 US GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 32 Mexico GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 35 UK GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 36 France GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 38 Spain GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 42 Asia Pacific GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 43 Japan GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 44 China GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 45 India GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 47 South Korea GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 48 Thailand GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 52 Middle East and Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait GLP-1 Agonists Weight Loss Drugs Market, 2018 - 2030 (USD Million)
  • Fig. 57 Company/Competition Categorization
  • Fig. 58 Company Market Share Analysis, 2024
  • Fig. 59 Company Market Position Analysis, 2024
  • Fig. 60 Strategy Mapping